Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 25 | 2023 | 728 | 7.040 |
Why?
|
| Kidney Failure, Chronic | 4 | 2024 | 880 | 1.530 |
Why?
|
| Depressive Disorder, Major | 4 | 2020 | 399 | 1.510 |
Why?
|
| Fatigue | 4 | 2023 | 191 | 1.130 |
Why?
|
| Sertraline | 4 | 2020 | 44 | 1.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 1270 | 1.040 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 504 | 0.970 |
Why?
|
| Forearm | 1 | 2024 | 45 | 0.920 |
Why?
|
| Hypertension | 3 | 2022 | 1329 | 0.910 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2024 | 101 | 0.850 |
Why?
|
| Diuretics | 2 | 2022 | 171 | 0.840 |
Why?
|
| Antidepressive Agents | 3 | 2020 | 293 | 0.840 |
Why?
|
| Renal Dialysis | 4 | 2024 | 854 | 0.830 |
Why?
|
| Veterans | 3 | 2023 | 1749 | 0.830 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 64 | 0.820 |
Why?
|
| Angioedema | 1 | 2023 | 22 | 0.820 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 432 | 0.810 |
Why?
|
| Renal Replacement Therapy | 2 | 2023 | 142 | 0.800 |
Why?
|
| Hyperkalemia | 1 | 2023 | 66 | 0.770 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 635 | 0.710 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 257 | 0.690 |
Why?
|
| Antihypertensive Agents | 2 | 2023 | 412 | 0.610 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 122 | 0.580 |
Why?
|
| Quality of Life | 4 | 2023 | 1934 | 0.550 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 428 | 0.540 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2017 | 109 | 0.530 |
Why?
|
| Vascular Calcification | 1 | 2017 | 57 | 0.530 |
Why?
|
| Blood Pressure | 2 | 2021 | 1369 | 0.510 |
Why?
|
| Humans | 36 | 2024 | 124936 | 0.500 |
Why?
|
| Troponin T | 1 | 2017 | 282 | 0.480 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 312 | 0.470 |
Why?
|
| Atherosclerosis | 2 | 2021 | 920 | 0.450 |
Why?
|
| Peptide Fragments | 1 | 2017 | 780 | 0.420 |
Why?
|
| Heart Failure | 2 | 2023 | 2297 | 0.410 |
Why?
|
| Proteinuria | 2 | 2024 | 101 | 0.400 |
Why?
|
| Urinalysis | 2 | 2024 | 61 | 0.400 |
Why?
|
| Sex Workers | 1 | 2012 | 5 | 0.400 |
Why?
|
| Inflammation | 1 | 2019 | 1442 | 0.390 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 1955 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2023 | 224 | 0.380 |
Why?
|
| Contact Tracing | 1 | 2012 | 54 | 0.380 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1327 | 0.380 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 91 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1265 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 732 | 0.360 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 800 | 0.350 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 108 | 0.340 |
Why?
|
| Obesity | 1 | 2021 | 2245 | 0.340 |
Why?
|
| Disease Progression | 3 | 2023 | 2058 | 0.330 |
Why?
|
| Middle Aged | 9 | 2024 | 26888 | 0.290 |
Why?
|
| Female | 13 | 2024 | 66672 | 0.270 |
Why?
|
| Male | 11 | 2024 | 61388 | 0.260 |
Why?
|
| Renin-Angiotensin System | 2 | 2023 | 101 | 0.250 |
Why?
|
| Creatinine | 3 | 2022 | 391 | 0.250 |
Why?
|
| Biomarkers | 3 | 2020 | 3080 | 0.250 |
Why?
|
| Hypoglycemic Agents | 3 | 2021 | 444 | 0.250 |
Why?
|
| Aged | 7 | 2024 | 19831 | 0.240 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1356 | 0.240 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 128 | 0.240 |
Why?
|
| Survival Analysis | 2 | 2019 | 1503 | 0.230 |
Why?
|
| Prognosis | 3 | 2019 | 4624 | 0.230 |
Why?
|
| Specific Gravity | 1 | 2024 | 4 | 0.230 |
Why?
|
| Reagent Strips | 1 | 2024 | 11 | 0.230 |
Why?
|
| Arm | 1 | 2024 | 81 | 0.220 |
Why?
|
| Adult | 8 | 2024 | 29587 | 0.220 |
Why?
|
| Depression | 3 | 2021 | 1236 | 0.220 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 37 | 0.210 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2023 | 35 | 0.210 |
Why?
|
| Prescriptions | 1 | 2023 | 40 | 0.200 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.200 |
Why?
|
| Chlorthalidone | 1 | 2022 | 27 | 0.200 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 36 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2024 | 16284 | 0.200 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 32 | 0.200 |
Why?
|
| Cystatin C | 1 | 2022 | 59 | 0.200 |
Why?
|
| Potassium | 1 | 2023 | 282 | 0.190 |
Why?
|
| Steroids | 1 | 2023 | 202 | 0.190 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 17 | 0.190 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 21 | 0.190 |
Why?
|
| Hematuria | 1 | 2022 | 54 | 0.190 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6583 | 0.180 |
Why?
|
| Glucosides | 1 | 2021 | 47 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 66 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2905 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2022 | 1562 | 0.150 |
Why?
|
| Risk Management | 1 | 2018 | 68 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 10270 | 0.140 |
Why?
|
| Albuminuria | 1 | 2017 | 100 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 221 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 438 | 0.130 |
Why?
|
| Self Report | 1 | 2019 | 517 | 0.130 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 398 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 2164 | 0.130 |
Why?
|
| Pandemics | 1 | 2023 | 1105 | 0.130 |
Why?
|
| United States | 4 | 2023 | 10899 | 0.120 |
Why?
|
| Cause of Death | 1 | 2017 | 474 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2022 | 4806 | 0.120 |
Why?
|
| Coronary Angiography | 1 | 2017 | 444 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12374 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1050 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 523 | 0.110 |
Why?
|
| Sex Factors | 1 | 2018 | 1286 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 873 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1112 | 0.100 |
Why?
|
| Comorbidity | 1 | 2018 | 1532 | 0.100 |
Why?
|
| Guatemala | 1 | 2012 | 63 | 0.100 |
Why?
|
| Sexual Partners | 1 | 2012 | 87 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 121 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2817 | 0.090 |
Why?
|
| Patient Preference | 1 | 2012 | 118 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1367 | 0.090 |
Why?
|
| Texas | 1 | 2017 | 3584 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2012 | 541 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2019 | 6145 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3449 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 6326 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3566 | 0.060 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 90 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1779 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2022 | 285 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2022 | 316 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 387 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 176 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7193 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 672 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 424 | 0.040 |
Why?
|
| Infant | 1 | 2012 | 12455 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 769 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 3134 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 1636 | 0.030 |
Why?
|